SEC Form 4 · accession 0001209191-18-028371
Horizon Pharma plc · HZNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Samuel Shannon
Director
Period of report
May 3, 2018
Accepted (ET)
May 7, 2018 · 5:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492426
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $13.87 | May 3, 2018 | A | 32,161 | A | — | May 2, 2028 | Ordinary shares | 32,161 | 32,161 | D |
| Restricted Stock UnitsF2 | — | May 3, 2018 | A | 15,320 | A | May 3, 2019 | — | Ordinary shares | 15,320 | 15,320 | D |
Explanation of responses
- F1The option vests in 12 equal monthly installments from the date of grant.
- F2Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.